Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...

Navrogen is a biotechnology company focused on the discovery of tumor-produced Humoral Immuno-Oncology (HIO) factors that are associated with suppressed humoral immunity, poor prognosis and limited ...

A new study reveals how bacteria in the gut can help determine whether the amino acid asparagine from the diet will feed ...

A new study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses. A Ludwig Cancer Research study has ...

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat ...

To investigate how FOXP3 dE2 affects tumor immune responses, Li and colleagues examined data from patients with triple-negative breast cancer in The Cancer Genome Atlas (TCGA) and analyzed survival ...

SSRIs enhance CD8 T cell antitumor activity by inhibiting SERT, an immune checkpoint in tumors, suggesting potential repurposing for cancer immunotherapy. High intratumoral SERT levels correlate with ...